CAS 941678-49-5

Ruxolitinib

Description:

Ruxolitinib is a small molecule drug classified as a Janus kinase (JAK) inhibitor, primarily used in the treatment of certain hematological malignancies, such as myelofibrosis and polycythemia vera. Its mechanism of action involves the selective inhibition of JAK1 and JAK2 enzymes, which play crucial roles in the signaling pathways of various cytokines and growth factors, thereby modulating immune responses and hematopoiesis. Ruxolitinib is typically administered orally and is known for its pharmacokinetic properties, including a moderate half-life and extensive metabolism primarily via the liver. Common side effects may include anemia, thrombocytopenia, and increased risk of infections due to its immunosuppressive effects. The drug has been pivotal in improving symptoms and quality of life for patients with myeloproliferative disorders. Additionally, ongoing research is exploring its potential applications in other inflammatory and autoimmune conditions, highlighting its versatility in therapeutic settings.

Formula: C₁₇H₁₈N₆

InChI: InChI=1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/t15-/m1/s1

InChI key: InChIKey=HFNKQEVNSGCOJV-OAHLLOKOSA-N

SMILES: [C@H](CC#N)(N1C=C(C2=C3C(=NC=N2)NC=C3)C=N1)C4CCCC4

Synonyms:

• (3R)-3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile
• (Betar)-Beta-Cyclopentyl-4-(7H-Pyrrolo(2,3-D)Pyrimidin-4-Yl)-1H-Pyrazole-1-Propanenitrile
• (R)-3-[4-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-3-cyclopentylpropanenitrile
• (βR)-β-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazole-1-propanenitrile
• 1H-Pyrazole-1-propanenitrile, β-cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-, (βR)-
• Inc 424
• Incb-018424
• R-Incb018424
• R-Ruxolitinib
• Ruxolitinib (INCB 018424)
• Ruxolitinib phosphate salt
• Ruxolitinib
• Ruxolitinib phosphate
• β-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyriMidin-4-yl)-(βR)-1H-pyrazole-1-propanenitrile
• Ruxolitinib INCB018424 Jakafi
• Ruxolitinib, >=98%
• (R)-Ruxolitinib (>90%)
• (3R)-3-(4-(7H-pyrrolo[2,3-d]pyriMidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
• 3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-pyrazol-1-yl]-propionitrile
• (R)-Ruxolitinib (INCB018424)
• (betaR)-beta-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazole-1-propanenitrile Ruxolitinib(INCB018424)
• INCB018424 (Ruxolitinib)
• 1H-Pyrazole-1-propanenitrile,.beta.-cyclopentyl-4-(7H-pyrrolo[2,3-d]pyriMidin-4-yl)-,(.beta.R)-
• Roxolitinib
• Jakafi
• Jakafi Ruxolitinib (INCB018424)

Ruxolitinib

CAS: 941678-49-5

Formula: C₁₇H₁₈N₆

Color and Shape: White To Off-White Solid

Molecular weight: 306.37

Ref: 4Z-R-093002

Ruxolitinib

CAS: 941678-49-5

Ruxolitinib

Formula: C₁₇H₁₈N₆

Purity: By hplc: 99.99% (Typical Value in Batch COA)

Color and Shape: solid

Molecular weight: 306.36502g/mol

Ref: 54-BIFK0027

Ruxolitinib

Controlled Product

CAS: 941678-49-5

Formula: C₁₇H₁₈N₆

Color and Shape: Neat

Molecular weight: 306.36

Ref: 86-MM3727.01

Ruxolitinib

CAS: 941678-49-5

Ruxolitinib (INCB018424) is a JAK1/2 inhibitor (IC50=3.3/2.8 nM) that is potent and selective.

Formula: C₁₇H₁₈N₆

Purity: 99.4% - >99.99%

Color and Shape: Solid

Molecular weight: 306.36

Ref: TM-T1829

Ruxolitinib (free base)

CAS: 941678-49-5

Ref: 7W-GW2265

Ruxolitinib-d4

CAS: 941678-49-5

Formula: C₁₇H₁₄N₆D₄

Molecular weight: 310.40

Ref: 4Z-R-093004

(R)-Ruxolitinib (>90%)

CAS: 941678-49-5

Applications Ruxolitinib is a selective Janus tyrosine kinase (JAK1 and JAK2) inhibitor used in the treatment of myeloproliferative neoplasms and psoriasis. Potent JAK2 inhibitor.
References Shilling, A.D. et al.: Drug Metab. Disp., 38, 2023 (2010); Mesa, R.A.: IDrugs, 13, 394 (2010); Campas-Moya, C.: Drugs Fut., 35, 457 (2010);

Formula: C₁₇H₁₈N₆

Purity: >90%

Color and Shape: White To Beige

Molecular weight: 306.36

Ref: TR-R702000

Ruxolitinib

CAS: 941678-49-5

Ruxolitinib is a janus tyrosine kinase inhibitor active specifically on sub-types JAK1 and JAK2 with IC50 values in the nanomolar range. JAK1 and JAK2 are kinases involved in the regulation of hematopoiesis. Clinically applied to the treatment of intermediate and high-risk myelofibrosis, ruxolitinib is usually well tolerated by patients.

Formula: C₁₇H₁₈N₆

Purity: Min. 95%

Color and Shape: White Powder

Molecular weight: 306.37 g/mol

Ref: 3D-FR27771

Ruxolitinib

CAS: 941678-49-5

Formula: C₁₇H₁₈N₆

Purity: 98%

Color and Shape: Solid

Molecular weight: 306.373

Ref: 10-F092499